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Abstract
C-reactive protein (CRP) has been studied extensively for association with a large number of non-infectious diseases and 
outcomes. We aimed to evaluate the breadth and validity of associations between CRP and non-infectious, chronic health 
outcomes and biomarkers. We conducted an umbrella review of systematic reviews and meta-analyses and a systematic 
review of Mendelian randomization (MR) studies. PubMed, Scopus, and Cochrane Database of Systematic Reviews were 
systematically searched from inception up to March 2019. Meta-analyses of observational studies and MR studies examin-
ing associations between CRP and health outcomes were identified, excluding studies on the diagnostic value of CRP for 
infections. We found 113 meta-analytic comparisons of observational studies and 196 MR analyses, covering a wide range 
of outcomes. The overwhelming majority of the meta-analyses of observational studies reported a nominally statistically 
significant result (95/113, 84.1%); however, the majority of the meta-analyses displayed substantial heterogeneity (47.8%), 
small study effects (39.8%) or excess significance (41.6%). Only two outcomes, cardiovascular mortality and venous throm-
boembolism, showed convincing evidence of association with CRP levels. When examining the MR literature, we found 
MR studies for 53/113 outcomes examined in the observational study meta-analyses but substantial support for a causal 
association with CRP was not observed for any phenotype. Despite the striking amount of research on CRP, convincing 
evidence for associations and causal effects is remarkably limited.
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Introduction
C-reactive protein (CRP) is one of the most widely used 
biomarkers in clinical practice. First identified in 1930 [1], 
this acute phase reactant was initially used as a biomarker for 
infection [2]. The advent of high-sensitivity CRP measure-
ment in the 1990s, alongside experimental and clinical evi-
dence suggesting a potential role of inflammation in cardio-
vascular disease a few years later [3, 4], increased research 
interest in CRP. It has since been examined as a potential 
risk factor for an ever-expanding list of diseases including 
different cardiovascular outcomes, cancers, metabolic and 
skeletal diseases and autoimmune diseases [5–9]. Today, 
despite intensive research efforts, the role of CRP in the 
etiology of common diseases remains unclear.
Umbrella review is a systematic overview of systematic 
reviews and meta-analyses that assesses the evidence from 
the current literature in a field of research [10]. We aimed 
to systematically summarize and evaluate the breadth and 
validity of associations between CRP and health outcomes 
using the umbrella review methodology. We summarized 
meta-analyses of observational studies, examined the extent 
of phenotypic associations with CRP, and evaluated the 
strength of associations and bias in these identified associa-
tions. At the same time, we performed a systematic review 
of Mendelian randomization (MR) studies considering CRP 
levels as the exposure, to assess the evidence for causality 
stemming from this literature.
Methods
Data sources and searches of observational studies
We systematically searched PubMed, Scopus, and Cochrane 
Database of Systematic Reviews, from inception to 31 March 
2019, for meta-analyses of observational studies examining 
the association of CRP with any health outcome (see search 
algorithms in Additional file 1: Appendix Table 1). All iden-
tified publications went through a three-step parallel review 
of title, abstract, and full text (performed by CK, GMa, SC, 
NK) based on predefined inclusion and exclusion criteria.
Study selection and data extraction 
of observational studies
We included systematic reviews and meta-analyses of 
observational studies that examined associations between 
CRP levels and health outcomes that had identified at least 
three studies per outcome examined, keeping only articles 
that were full publications and in the English language. We 
excluded studies without systematic literature searches (for 
meta-analyses of observational studies), without quantitative 
synthesis of effect sizes, and studies where CRP concentra-
tions were the outcome. Also, due to the well-known role of 
CRP in infectious disease diagnosis, articles which investi-
gated infections as the outcome of interest were excluded. 
We also excluded meta-analyses using only cross-sectional 
assessments, meta-analyses of only crude (unadjusted) esti-
mates, and associations reported as correlation coefficients. 
Where more than one article with overlapping outcomes was 
retrieved, the article with the meta-analysis of only prospec-
tive studies, the most comprehensive meta-analysis (the one 
including the largest number of studies), or the more recently 
published one was included in the final analysis (in order of 
preference).
Three independent investigators (CK, GMa and SC) 
extracted the data, which were checked by a second inves-
tigator (IT, ET) and in case of discrepancies consensus was 
reached. From each eligible meta-analysis, we extracted 
information on the first author, journal and year of pub-
lication, examined risk factors and the number of studies 
considered, type of metric reported (hazard ratio, risk ratio, 
odds ratio [OR], in order of preference), maximally adjusted 
effect sizes and 95% confidence intervals (CIs), number of 
total studies included, design of the original studies, unit 
of comparison, number of cases and population. When the 
number of cases or controls for individual studies was not 
reported, we abstracted them from the original studies when 
possible. When CRP was examined in more than one level of 
comparison (e.g. as a continuous biomarker and by tertiles), 
we extracted the data for the comparison having the largest 
number of component studies.
Data synthesis and analysis of meta‑analyses 
of observational studies
For meta-analyses of observational studies, we estimated the 
summary effects obtained from the random-effects method 
[11, 12] for which we also estimated the 95% prediction 
intervals to indicate the possible interval that could include 
the effect size of a new study examining the same associa-
tion and describe the uncertainty of the summary effect size 
[13]. The heterogeneity between studies was assessed using 
the  I2 metric, which has a range between 0 and 100%. It is 
calculated as the ratio of the variance between-studies over 
the sum of the variances between and within studies [14]. 
Values exceeding 50% or 75% are considered to represent 
large or very large heterogeneity, respectively. Small study 
effects were assessed with the use of the Egger’s regression 
asymmetry test [15]. A P ≤ 0.10 combined with a more con-
servative effect in the largest study than in random-effects 
meta-analysis was judged to provide evidence for small-
study effects.
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We further applied the excess statistical significance 
test, which evaluates whether there is a relative excess of 
formally significant findings in the published literature due 
to any reason (e.g., publication bias, selective reporting of 
outcomes or analyses) [16]. It is a Chi square-based test 
that assesses whether the observed number of studies with 
nominally significant results is larger than their expected 
number. We used the effect size of the largest study (smallest 
standard error) in each meta-analysis to calculate the power 
of each study using a non-central t distribution. Excess sta-
tistical significance was claimed at two-sided P ≤ 0.10 with 
observed > expected as previously proposed [16, 17].
Quality assessment and evidence grading 
of observational studies
We classified the evidence of the associations that had 
P < 0.05 as strong, highly suggestive, suggestive, and weak 
based on a set of previously used criteria whose rationale 
has been described elsewhere in detail [10, 18–20]. In brief, 
these criteria try to consider the level of statistical signifi-
cance, amount of evidence, consistency, and lack of signals 
of bias. Thus, we classified as strong evidence those associa-
tions that had significance P < 1×10−6 based on the random 
effects model, more than 1000 cases, the  I2 metric was less 
than 50%, there was no evidence of small study effects, the 
prediction interval did not include the null value, and there 
was no evidence for excess significance bias. Associations 
were classified as highly suggestive when P < 1×10−6 based 
on the random-effects model, more than 1000 cases, and the 
P value of the largest study in the meta-analysis was < 0.05. 
The associations with P < 0.001, and more than 1000 cases 
were considered as suggestive. Finally, associations were 
considered as weak when P < 0.05 on the random effects 
model.
Some meta-analyses used estimates from studies with 
different study designs. Due to the inherent limitations of 
cross-sectional and case–control studies to examine temporal 
associations, we performed a sensitivity analysis by exclud-
ing cross-sectional and case–control studies.
Finally, for each association in the strong and highly sug-
gestive category, we reassessed the evidence after examin-
ing each meta-analysis in depth by assessing the eligibility 
of the included studies as well as verifying the data used in 
the meta-analysis using AMSTAR (A MeaSurement Tool to 
Assess systematic Reviews) [21].
Data sources and searches, study selection and data 
extraction of Mendelian randomization studies
We used the search algorithm (See Additional file 1: Appen-
dix Table 1) to identify MR studies evaluating potential 
causal association between CRP levels and health outcomes, 
excluding infections. The titles, abstracts, and full texts of 
the resulting papers were examined in detail by two authors 
(GMa and IT), and discrepancies were resolved by consen-
sus. From each eligible MR study, two authors (GMo and 
GMa) extracted data in relation to first author, journal and 
year of publication, the study cohort/s, sample size, num-
ber of cases (as applicable), type of data used (individual 
participant or summary level), the instrumental variables 
(single-nucleotide polymorphisms [SNPs]), the instrument 
selection approach, population ancestry, SNP exclusion cri-
teria,  % variance explained by the instruments, the outcome 
phenotypes, the MR effect estimate and the corresponding 
CIs. When we observed a nominally significant association 
(P < 0.05) in the main MR analysis, we further extracted and 
evaluated all information on sensitivity MR analyses.
Evidence grading of Mendelian randomization 
studies
We stratified MR analyses into those using instrumental 
variables which included only variants located in the CRP 
gene and those using instrumental variables with SNPs that 
were significantly associated with CRP levels from through-
out the genome (i.e., not restricted to the CRP gene). The 
latter approach for selecting instruments is more likely to 
incorporate invalid instruments that have pleiotropic effects 
[22]. Indeed, a genome-wide association study (GWAS) of 
CRP has revealed a large number of genetic variants, which 
were not specific to CRP, but influence other inflammatory 
cytokines including interleukin-6 receptor (IL-6R) and inter-
leukin 1 family member 10 (ILF10) [23]. For MR analyses 
restricted to variants located in the CRP gene, we consid-
ered MR evidence as ‘potentially supportive’ when the main 
analysis reported a P < 0.01 [20] and there was consistent 
evidence from sensitivity analyses; ‘limited/inconsistent evi-
dence’ when there was 0.01 < P < 0.05 or P < 0.01 without 
further support from sensitivity analysis, and ‘not present’ 
when P > 0.05. For MR analyses with variants throughout 
the genome for CRP, we considered as ‘limited/inconsistent 
evidence’ when there was P < 0.05 and further support from 
sensitivity analysis, and ‘not present’ otherwise.
Results
CRP levels and health outcomes reported 
in meta‑analyses of observational studies
Our literature search yielded 4100 eligible articles. Fol-
lowing title review, 863 articles were considered eligible 
(Fig. 1), and after abstract screening, 552 articles were 
potentially eligible for full text review. Finally, 55 studies 
[5, 24–77] including 113 comparisons of different outcomes 
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were included in the umbrella review of observational 
studies, consisting of 952 primary estimates. To facilitate 
interpretation, the different outcomes were classified into 
the following groups: cancer-related (52 outcomes), car-
diovascular-related (31 outcomes), kidney-related (7 out-
comes), skeletal (6 outcomes), neurological (3 outcomes), 
pregnancy-related (2 outcomes), respiratory-related (2 out-
comes), and other (10 outcomes).
The majority of the primary studies were cohorts 
(N = 823; 86.5%, of which 497 were prospective, 264 retro-
spective, and 62 of unclear design), followed by case–control 
studies (N = 115; 12.1%). Other study designs consisted of 
Fig. 1  Flowchart of study selection for a umbrella review and b Mendelian Randomization review
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cross-sectional studies (N = 6; 0.6%), case-cohorts (N = 7; 
0.7%), and one case-crossover study (0.1%).
Ninety-five out of 113 associations (84.1%) presented 
a statistically significant effect at P < 0.05 under the ran-
dom-effects model, 67 remained significant at P < 0.001, 
whereas 34 associations had a statistically significant effect 
at P < 1×10−6 (Table 1). However, only 24 (21.2%) associa-
tions had a 95% prediction interval that excluded the null. 
The largest study was statistically significant in 71 of the 
113 comparisons (62.8%) and was more conservative than 
the meta-analysis estimate in 87 of 113 comparisons (77%) 
(Table 1). Twenty-three associations (20.4%) presented 
very large between-study heterogeneity  (I2 > 75%), and 
31 (27.4%) associations had large heterogeneity estimates 
 (I2 > 50% and  I2 < 75%). In 45 (39.8%) of the 113 associa-
tions the Egger’s test was statistically significant (P < 0.1) 
and the random effects estimate was inflated compared to 
the largest study (Table 1). Forty-seven associations (41.6%) 
showed evidence of excess significance, meaning that the 
number of observed studies with statistically significant 
results exceeded the number of expected ones (Table 1).
Assessment of epidemiological credibility
Of the 113 associations, only two cardiovascular outcomes 
(cardiovascular mortality and venous thromboembolism) 
fulfilled the necessary criteria to be categorized in the 
strong level of evidence (Table 1). Ten (8.9%) associations 
were supported by highly suggestive evidence, 6 of which 
were on cardiometabolic outcomes. The highly suggestive 
associations were all-cause mortality in general population, 
all-cause mortality in patients with chronic kidney disease, 
long-term mortality in chronic obstructive pulmonary dis-
ease (COPD) patients, long-term mortality or CVD in acute 
coronary syndrome (ACS)/unstable coronary heart disease 
(CHD)/angina patients, mortality or CVD in stable coronary 
artery disease (CAD) patients, CHD in general population, 
overall survival in hepatocellular carcinoma patients, Bath 
Ankylosing Spondylitis Disease Activity Index-50 (BAS-
DAI50) in ankylosing spondylitis patients, ovarian cancer in 
general population, and type 2 diabetes in general popula-
tion. There were 16 comparisons that were categorized in 
the suggestive level of evidence and 67 in the weak level. 
Finally, 18 comparisons did not present a statistically sig-
nificant association. When we excluded the case–control 
or cross-sectional studies, only seven comparisons were 
affected. Only six of those comparisons had at least 3 
remaining studies in order to be re-evaluated and for all six 
the evidence categorization remained the same (Additional 
file 1: Appendix Table 2).
When we assessed the meta-analyses in either the strong 
or the highly suggestive evidence category, we observed that 
the majority of the meta-analysis papers were on moderate 
study quality (9 of the 11 papers) based on an AMSTAR 
score between 4 and 7, and only one had a score of 8. Finally, 
one study [41] was a pooled analysis and therefore it could 
not be evaluated based on the AMSTAR tool (Additional 
file 1: Appendix Table 3).
CRP levels and health outcomes reported 
in Mendelian randomization studies
A total of 196 primary MR analyses were identified from 37 
studies [79–115] covering 82 distinct phenotypes (Table 2 
and Additional file 1: Appendix Tables 4, 5). The majority 
of associations were investigated through two-sample MR 
methodologies (130 out of 196; 66%). The median number 
of participants included in MR studies was 26 405 (range 
134 to 184 305). The most frequently examined phenotypes 
included cardiovascular diseases (coronary heart disease and 
stroke) (n = 19; 9.7%), type 2 diabetes (n = 8; 4.1%), schizo-
phrenia (n = 8; 4.1%), and body mass index (BMI) (n = 6; 
3.1%). Eighty-four MR analyses (60 unique outcomes, 
Table 2) used instrument variants at the CRP gene locus, 
and 112 used instruments from throughout the genome The 
SNPs used as instruments varied vastly among studies. The 
four most commonly used SNPs among the 196 MR associa-
tions were rs1130864 (n = 78; 39.8% of the comparisons), 
rs1205 (n = 74; 37.8%), rs2794520 (n = 74; 37.8%), and 
rs3093077 (n = 65; 33.2%); all these variants fall within or 
close the CRP gene region.
Overall, 12 distinct phenotypes presented significant 
associations at a P < 0.01, of which four (Crohn’s disease, 
ischemic heart disease, systolic and diastolic blood pres-
sure) presented significant associations (P < 0.01) when the 
instruments were restricted to CRP gene locus (Appendix 
Tables 4 and 5). However, independent MR analyses did not 
show consistent evidence for Crohn’s disease and ischemic 
heart disease, and none of the aforementioned phenotypes 
had support from sensitivity analyses.
Nine phenotypes presented significant (P < 0.01) causal 
effect estimates when instruments from throughout the 
genome were considered and of those, only schizophrenia 
and bipolar disorder presented consistent evidence in sen-
sitivity analyses and in analysis restricted to SNPs within 
CRP locus, but only at P < 0.05. Nonetheless, the result 
on bipolar disorder [113] was not confirmed by an earlier 
study [107] where MR using only CRP gene SNPs did not 
reach statistical significance at P < 0.05. Schizophrenia had 
evidence from independent studies and sensitivity analysis 
(weighted median and inverse variant weighted estimate), 
but this was not supported by MR Egger analysis and the 
sensitivity analysis using only CRP gene SNPs (P = 0.04).
Overall, only 14 outcomes had evidence available from 
both MR analyses and meta-analyses of observational 
studies (Table 3). The evidence between the observational 
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studies and MR analyses was concordant for three out-
comes where both meta-analyses of observational studies 
and MR analyses were not statistically significant (P ≥ 0.05). 
The remaining studies showed various degree of evidence 
(weak, suggestive, highly suggestive) with meta-analyses of 
observational studies and no evidence or limited inconsistent 
evidence from MR. Finally, MR did not support causality for 
venous thromboembolism whose evidence was graded as 
strong in the observational meta-analysis evidence.
Conclusions
Our umbrella review showed an impressive body of litera-
ture on CRP including 113 comparisons from 55 studies for 
separate phenotypes and 196 MR analyses to assess causality 
of epidemiologic associations. Only 14 phenotypes had evi-
dence from meta-analysis of observational studies and MR 
analyses. Most summary meta-analytic estimates of obser-
vational studies yielded nominally statistically significant 
results for a direct association between CRP and different 
phenotypes. Nonetheless, only two of these associations had 
strong results with no suggestions of biases (cardiovascular 
mortality and venous thromboembolism in general popula-
tion) and none of these had supporting evidence of a causal 
role for CRP in MR investigations.
Low-grade inflammation has been suggested to be 
involved in many chronic diseases, which may explain the 
breadth and depth of phenotypes examined in relation to 
CRP, a general marker of inflammation that can be inexpen-
sively measured in epidemiological and clinical settings. A 
search of “C-reactive protein or CRP” yields 74,622 items 
as of March 05, 2019, and the vast number of meta-analy-
ses that we identified are efforts to summarize this huge, 
expanding literature.
A large proportion of studies examined CRP as a prognos-
tic marker of cancer incidence but also of cancer survival. 
Out of those 52 comparisons, there was highly suggestive 
evidence for only two associations (ovarian cancer incidence 
and overall survival in hepatocellular carcinoma). The evi-
dence from the remaining literature was classified as sugges-
tive or weak. MR efforts, including one on lung cancer, did 
not highlight any evidence of causality either, although their 
sample sizes were modest for less common cancers. Chronic 
inflammation may still be linked to cancer development and 
progression, as other lines of evidence suggest a higher risk 
of cancer amongst individuals with inflammatory conditions 
(e.g., inflammatory bowel diseases and risk of colon cancer), 
or higher risk of cancer in relation to infections (e.g. human 
papillomaviruses and cervix cancer) [115–119]. However, 
CRP, as a general marker of inflammation, is unlikely to 
capture the specific inflammatory mediating pathways link-
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CRP and cardiovascular diseases have been subject to an 
increasing body of research and debate. Our review found 
that the associations of CRP with cardiovascular mortal-
ity and venous thromboembolism were supported by strong 
evidence. Furthermore, we found highly suggestive evidence 
between higher CRP and risk of CHD, type 2 diabetes and 
mortality or CVD on stable CAD patients and on unstable 
CHD/ACS/angina patients. Nonetheless, MR studies have 
repeatedly failed to provide evidence for causal association 
with CHD; an observation further supported from rand-
omized controlled trials [120]. The observational literature 
of CRP is likely to suffer from diverse biases and the effect 
size of the associations may be inflated [121, 122]. Beyond 
causality, even efforts to show that CRP could at least be 
used in risk prediction have also not demonstrated convinc-
ing results [123, 124]. Accordingly, the relative risks that we 
noted for cardiovascular mortality (2.05, in fact just 1.49 in 
the largest study) and venous thromboembolism (only 1.14) 
do not suggest a substantial predictive potential. The role of 
inflammation in atherosclerotic plaque initiation, progres-
sion and rupture has been supported by various other lines 
of evidence [125], but this may not necessarily prove that 
CRP should have clinical utility.
COPD is associated with an abnormal inflammatory 
response beyond the lungs with evidence of low-grade 
systemic inflammation which causes systemic manifesta-
tions such as weight loss, skeletal muscle dysfunction, an 
increased risk of cardiovascular disease, osteoporosis and 
depression [125–128]. We found highly suggestive evidence 
that CRP is associated with late (but not with early) mortal-
ity in COPD patients. However, MR studies did not support 
a causal association. CRP might be elevated in COPD 
patients due to reverse causality as the disease is associated 
with triggering an inflammatory response. Reverse causality 
is likely to explain other associations such as mortality in 
patients with chronic kidney disease or overall survival in 
hepatocellular carcinoma patients. In these instances CRP 
could serve as a predictive factor for disease severity, but 
studies assessing its value over and above validated exist-
ing risk prediction algorithms are essential to support any 
prediction claim [123].
Some particular mention needs to be made on schizo-
phrenia, where, among the tentative MR findings described 
in this review we found several studies of CRP and schizo-
phrenia onset. Yet, there is a distinctive lack of observa-
tional data on this association, and those that exist [129, 
130], mainly focus on the reverse pathway of the associa-
tion (how schizophrenia affects CPR levels) than what is the 
focus of this review.
In our MR review we found multiple studies and sensitiv-
ity analyses show evidence for causal effect, but with very 
modest P-values, when only CPR SNPs were used in the 
genetic instruments. One recent analysis (published after the 
search date of our review [131]) found even lower P-values 
with inverse variance weights and generalized summary MR 
modeling. The putative causal association with schizophre-
nia is even more interesting because it suggests a protective 
effect of CRP on schizophrenia, while observational data 
had suggested an association of CRP with higher schizo-
phrenia risk [130].
Overall, the overwhelming majority of the meta-analyses 
of observational studies reported a nominally statistically 
Table 3  Comparison of evidence from observational studies meta-analysis and Mendelian randomization (MR) studies taking into account both 
CRP gene-only and genome-wide significant instruments
Population (observational) Outcome (observational) Grade (observational) Outcome (MR) Grade (MR)
General population Venous thromboembolism Strong Venous Thromboembolism No evidence
General population All-cause mortality Highly suggestive All-cause mortality No evidence
General population Coronary Heart Disease Highly suggestive Coronary Heart Disease No evidence
General population Type 2 diabetes Highly suggestive Type 2 diabetes Limited/inconsistent evidence
General population Hypertension Suggestive Hypertension No evidence
General population Ischemic stroke Suggestive Ischemic stroke (all types) No evidence
AF patients Atrial fibrillation (recur-
rence)
Weak Atrial fibrillation No evidence
General population Alzheimer’s disease Weak Alzheimer’s disease Limited/inconsistent evidence
General population 
(women)
Breast cancer Weak Breast cancer No evidence
General population Colon cancer Weak Colon cancer No evidence
General population Colorectal cancer Weak Colorectal cancer Limited/inconsistent evidence
Vascular surgery patients Non-fatal Myocardial 
Infarction
No evidence Non-fatal Myocardial 
Infarction
Limited/inconsistent evidence
General population (men) Prostate cancer No evidence Prostate cancer No evidence
General population Rectal cancer No evidence Rectal cancer No evidence
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significant result (84%) in contrast to MR studies where only 
37 of the 196 (19%) analyses presented nominally statisti-
cally significant results. These two study designs may be 
subject to different biases in the biomedical field. A large 
proportion (48.2%) of the examined observational meta-
analyses displayed substantial heterogeneity  (I2 > 50%), 
small study effects (39.5%), and excess significance bias 
(41.2%), which, in addition to the small effect estimates 
increase the probability of false-positive findings. MR 
approaches use genetic variants as instrumental variables 
to establish whether an exposure is causally related to a dis-
ease or trait. The genetic variants are unrelated to confound-
ing factors, and therefore, this approach is not as prone to 
confounding and reverse causation bias. At the same time, 
genetic association estimates in MR represent the average 
lifetime association of the variants with the outcome for all 
those in the considered population, and are therefore less 
vulnerable to measurement error [132]. Nonetheless, MR 
also shares some of the limitations of observational epi-
demiology literature including small sample sizes, instru-
ment bias and low power, and poor reporting has further 
additional limitations [22]. For example, we observed that 
at least half of the MR studies on CRP used instruments 
derived from genome-wide association studies including 
genetic variants on genes of other inflammatory cytokines 
such as IL-6. These approaches may introduce potential plei-
otropy and can thus bias MR estimates. There are several 
methodologies to account for the violation of the pleiotropy 
assumption of MR, but these cannot always identify pleio-
tropic effects, and therefore, can only partly disentangle the 
complex pleiotropy previously shown between CRP and 
lipid and metabolic pathways [133].
Limitations of our approach need to be acknowledged. 
Our review focused on existing meta-analyses, and there-
fore, outcomes that were not assessed in a meta-analysis 
are not included in this review. Furthermore, we did not 
appraise the quality of the individual studies but the quality 
of the actual meta-analyses. We refer interested readers to 
the quality assessments already made by the authors of each 
original meta-analysis and we did not wish to change the 
eligibility criteria based on quality since this would add our 
own subjective in study selection. We did not include evi-
dence from randomised control trial meta-analyses as these 
examine a wide range of anti-inflammatory treatments which 
are not specific to CRP lowering effects. Statistical tests for 
small-study effects and excess significance bias should also 
be interpreted with caution in case of large between-study 
heterogeneity and both tests have limited power in the pres-
ence of few studies or sparse studies with significant results. 
Finally, we adopted credibility assessment criteria, which 
were based on established tools for observational evidence; 
however, none of the components of these criteria provides 
firm proof of credibility of evidence, but they cumulatively 
describe the possibility that the results are susceptible to 
bias and uncertainty.
In this extensive systematic review of meta-analyses of 
observational studies on CRP and disease outcomes and of 
the evidence stemming from MR studies, we could not find 
strong evidence supported by both study designs in rela-
tion to CRP and the most frequently studied non-infection 
phenotypes in the literature. Observational studies presented 
robust evidence of association between higher CRP levels 
and cardiovascular mortality and venous thromboembolism, 
but without causality support from MR studies. Following 
claims that CRP maybe be a novel CVD risk factor [134], it 
has been extensively studied in relation to an ever-increas-
ing list of phenotypes and diseases, but it does not seem 
to be crucially relevant to any of them. Despite intensive 
research efforts, our study shows that there is little evidence 
that CRP may constitute a priority interventional target for 
any diseases.
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